CT-0508 + Pembrolizumab
HER2-overexpressing solid tumors
Key Facts
Indication
HER2-overexpressing solid tumors
Phase
Phase 1
Status
Active, recruiting
Company
About Carisma Therapeutics
Carisma Therapeutics is focused on developing a new class of immunotherapies by engineering macrophages, which are innate immune cells capable of infiltrating solid tumors and modulating the tumor microenvironment. The company's lead candidate, CT-0508, is in Phase 1 clinical trials for HER2-overexpressing solid tumors, representing a first-in-class approach. Carisma has established strategic collaborations with industry leaders like Moderna and Sesen Bio to expand its platform and pipeline. Despite being a clinical-stage company with no approved products, it has attracted significant investment and attention for its innovative technology.
View full company profileTherapeutic Areas
Other HER2-overexpressing solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CT-0508 | Carisma Therapeutics | Phase 1 |